DELRAY BEACH, Fla. - April 25, 2012 (Investorideas.com newswire) - PositiveID Corporation's (
OTCBB:PSID)
iglucose was named a finalist in the Healthcare and Wellness Category
of CTIA's annual Emerging Technology (E-Tech) Awards competition. The
CTIA E-Tech Awards honor the most innovative new products in 15
categories spanning the areas of mobile apps, consumer electronics,
enterprise and infrastructure. Winners, including Best in Show and Best
Online Pick, will be announced on Wednesday, May 9 at 2:00 p.m. CDT by
Jon Fortt, technology correspondent for CNBC on the Exhibit Innovations
Stage at International CTIA WIRELESS, taking place May 8--10, 2012 at
the Ernest N. Morial Convention Center in New Orleans.
Hundreds of entries were judged by a panel of recognized industry
experts, media and analysts and scored on innovation, functionality,
technological importance, implementation and overall "wow" factor.
"We are honored iglucose was chosen as a finalist among entries
from much larger companies including Alcatel-Lucent, AT&T, HTC,
Motorola, Nokia Siemens, Samsung, Qualcomm and others," stated Mary
Ellen Harrison, Vice President of Health ID at PositiveID.
Simplicity sets iglucose apart from other mobile health solutions.
iglucose can be used by consumers of any technical skill level. It is
easy to use and conveniently fits within a pocket or purse. Usability
tests conducted as
part
of the iglucose FDA review process demonstrated 100 percent of
consumers were able to use the device regardless of their age. After
initial enrollment there are no technology requirements for the end
user. Consumers simply connect their glucometer to iglucose and push a
button. The iglucose system creates a variety of reports and
communicates according to each individual's preferences via online
access, email, fax or SMS text.
PositiveID's FDA-cleared iglucose uses mobile technology to
revolutionize the way individuals with diabetes manage their condition.
By seamlessly communicating data from glucometers to the iglucose
diabetes management portal, glucose readings can be shared with family
members and healthcare professionals, making it possible to improve care
in a cost-effective manner. iglucose eliminates the burden of keeping
logbooks and empowers individuals with diabetes to be more engaged in
the self-management of their condition. Family members have greater
peace of mind; now parents of children with diabetes can receive text
messages to let them know their children are testing while at school.
iglucose does not require the use of a cell phone or a wireless plan.
Between now and May 8, website visitors may vote for the "Best
Online Pick" at www.ctiashow.com/awards. International CTIA WIRELESS
show attendees will vote onsite via text message for entries in the
E-Tech Awards showcase in Booth 4575 at the Emerging Technology Zone to
win "Best in Show."
To vote for iglucose visit
http://ctiait.ctia.org/etech/2012/public/index.cfm/viewEntry/617. To learn more about iglucose visit
www.iglucose.com or email
info@iglucose.com.
For more information on the E-Tech Awards, visit
www.ctiashows.com/awards.
For additional details and a comprehensive look at the CTIA conference program, visit:
www.ctiawireless.com. Members of the media may pre-register for full access to all show events at:
www.ctiashows.com/pressreg.
Follow CTIA Shows:
Facebook:
www.ctiashows.com/facebook
LinkedIn:
www.ctiashows.com/linkedin
Twitter:
www.ctiashows.com/twitter (#CTIAW12)
About CTIA Shows
CTIA Shows bring together all industries advanced by wireless
technology for intense business, learning and networking. International
CTIA WIRELESS(R) takes place May 8-10, 2012 at the Ernest N. Morial
Convention Center in New Orleans, La. CTIA ENTERPRISE &
APPLICATIONS(TM) takes place Oct. 9-11, 2012 at the San Diego Convention
Center in San Diego, Calif. Visit
www.ctiashows.com.
About CTIA
CTIA--The Wireless Association(R) (
www.ctia.org)
is an international organization representing the wireless
communications industry. Membership in the association includes wireless
carriers and their suppliers, as well as providers and manufacturers of
wireless data services and products. CTIA advocates on behalf of its
members at all levels of government. The association also coordinates
the industry's voluntary best practices and initiatives, and sponsors
the industry's leading wireless tradeshows. CTIA was founded in 1984 and
is based in Washington, D.C.
The CTIA Wireless Association logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=12582
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced
technologies for diabetes management and rapid medical testing, as well
as airborne bio-threat detection systems for America's homeland defense
industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is
focused on the development of microfluidic systems for the automated
preparation of and performance of biological assays in order to detect
biological threats at high-value locations, as well as analyze samples
in a medical environment.
For more information on PositiveID, please visit
http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the
likelihood that PositiveID's M-BAND system is well positioned to take
part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be
released in the first half of 2012, and is the only system of its kind
that was demonstrated in the field under the DHS S&T BAND Program;
the likelihood that M-BAND was the only successful system to emerge from
the BAND program; the likelihood that the M-BAND instrument offers a
number of advantages including decreased consumable and operating costs,
a small footprint, a closed operating environment and significant
flexibility of operation; the likelihood that M-BAND is the only system
of its kind that has been successfully field tested indoors and
outdoors, both domestically and internationally; the likelihood that
M-BAND has significant benefits that set this technology apart and put
PositiveID in a strong position to participate with large partners in
the $3.1 billion BioWatch opportunity; and all other statements in this
press release other than historical facts are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of
1933, Section 21E of the Securities Exchange Act of 1934, and as that
term is defined in the Private Litigation Reform Act of 1995. Such
forward-looking statements involve risks and uncertainties and are
subject to change at any time, and PositiveID's actual results could
differ materially from expected results. These risks and uncertainties
include PositiveID's ability to successfully participate in the $3.1
billion BioWatch opportunity; as well as certain other risks. Additional
information about these and other factors that could affect the
Company's business is set forth in the Company's various filings with
the Securities and Exchange Commission, including those set forth in the
Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13,
2011, August 15, 2011, and November 14, 2011, under the caption "Risk
Factors." The Company undertakes no obligation to update or release any
revisions to these forward-looking statements to reflect events or
circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
Disclaimer/ Disclosure: Disclaimer: Our sites do
not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt
to research thoroughly, but we offer no guarantees as to the accuracy
of information presented. All Information relating to featured companies
is sourced from public documents and/ or the company and is not the
opinion of our web sites. This site is currently compensated by featured
companies, news submissions and online advertising. PositiveID
Corporation (
OTCBB:PSID)
featured biotech company on Investorideas.com for 3 months effective
January 30,2012 . Compensation: two hundred fifty thousand 144 shares
for news release publication, syndication on blogs and related sites and
email distribution and company profile . More info:
www.InvestorIdeas.com/About/Disclaimer.asp and disclosures:
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
Exceed Company Ltd. designs, develops and engages in wholesale of
footwear, apparel and accessories under its own brand, XIDELONG, in
China. Since it began operations in 2002, Exceed has targeted its growth
on the consumer markets in the second and third-tier cities in China.
Exceed has three principal categories of products: (i) footwear, which
comprises running, leisure, basketball, skateboarding and canvas
footwear, (ii) apparel, which comprises sports tops, pants, jackets,
track suits and coats, and (iii) accessories, which comprise bags,
socks, hats and caps 
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company
focused on improving patients' lives by identifying, developing and
commercializing products that address unmet medical needs. The company
has a diverse portfolio of products in the areas of narcolepsy, pain,
psychiatry and women's health. The company's marketed products in these
areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal
infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine
maleate) and Elestrin® (estradiol gel 0.06%). 
Investors - sign up for free green stocks trading alerts and news 
Research more China and tech stocks with Investorideas.com stock directories: